Advicenne SA is a pharmaceutical company, which engages in the development of innovative treatments in Nephrology. The company is headquartered in Paris, Ile-De-France and currently employs 15 full-time employees. The company went IPO on 2017-12-06. The firm focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company’s medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.
Follow-Up Questions
Advicenne SA のCEOは誰ですか？
Mr. Didier Laurens は Advicenne SA の Chief Executive Officer で、2021 から在籍しています。
ADVVF の株価パフォーマンスは？
ADVVF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Advicenne SA の主な事業テーマや業界は？
Advicenne SA は Pharmaceuticals 業界、セクターは Health Care に属しています。
